Moderna, Inc.MRNA
Health Care · Pharmaceuticals, Biotechnology & Life Sciences · NASDAQ · United States · modernatx.com
Moderna, Inc. is a US biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, with commercial products including Spikevax (COVID-19 vaccine) and mRESVIA (RSV vaccine). The company has over 35 mRNA candidates in clinical development spanning infectious diseases, oncology, cardiovascular disease, and rare genetic disorders.
Key ratios
FCF / Sales
-106.2%TTM
2025
-106.2%2024
-125.3%2023
-55.9%
Net margin
-145.2%TTM
2025
-145.2%2024
-110.0%2023
-68.8%
ROA
-14.5%TTM
2025
-14.5%2024
-15.1%2023
-12.0%
ROE
-28.9%TTM
2025
-28.9%2024
-28.8%2023
-28.6%
Recent news
Moderna Science Day Highlights Expanding Potential of mRNA Platform
Moderna flu vaccine wins unanimous support from FDA panel
Track MRNA in your journal
Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.
Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer